Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

The efficacy of vardenafil in ED is not affected by glycemic control or diabetes

July 1, 2004

Theravance presents new muscarinic M2 antagonists with utility in overactive bladder

June 28, 2004

New IP receptor antagonists and their use in urological disorders claimed by Bayer

June 28, 2004

Senetek licenses Invicorp to Ardana for Europe

June 28, 2004

European approval for Watson's oxybutynin transdermal product

June 23, 2004

Levitra enters Japanese market

June 21, 2004

NCX-911 may benefit ED patients with dysfunctional endogenous NO production

June 18, 2004

Dopamine D4 receptor agonist ABT-724 may offer safe and effective treatment of erectile dysfunction

June 18, 2004

SVT-40776 progresses into phase II for urinary incontinence

June 17, 2004

Sosei's phase I trial of SOU-001 cleared to begin in U.K.

June 17, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...